Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs AT&T Inc. (T) Price & Performance

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs AT&T Inc. — how do they compare? Novartis AG trades at $138.17 (market cap $262.64B), while AT&T Inc. trades at $25.2 (market cap $175.42B). The key difference: Novartis AG is the larger of the two by market cap, and AT&T Inc. pays the higher dividend (4.34%). Which is the better fit depends on your goals.

NVST
Market Cap
$262.64B$175.42B
Sector
HealthMedia
52-Week High
$168.62$29.62
52-Week Low
$121.80$20.49
Enterprise Value
$303.97B$320.74B
Dividend Yield
3.44%4.34%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

AT&T Inc.

AT&T (T) trades at $25.61, down slightly by 0.21% on the day. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company reported robust earnings, beating estimates in recent quarters, with a net income margin of 16.94% and attractive valuation ratios like a P/E of 8.45. Recent news highlights strategic focus on fiber and wireless growth, including a partnership with Amazon for satellite broadband.

The outlook for AT&T is positive, supported by consistent earnings beats, a solid dividend, and strategic initiatives in fiber and 5G. Key risks include high debt levels and intense competition. Analysts maintain a consensus buy rating with a $27.69 price target, suggesting potential upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About AT&T Inc.

AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.

Read more on T